Cargando…
The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines
BACKGROUND: High-risk neuroblastoma with N-Myc amplification remains a therapeutic challenge in paediatric oncology. Antagonism of pro-death Bcl-2 homology (BH) proteins to pro-survival BH members such as Mcl-1 and Bcl-2 has become a treatment approach, but previous studies suggest that a combined i...
Autores principales: | Klenke, Stefanie, Akdeli, Neval, Stelmach, Patrick, Heukamp, Lukas, Schulte, Johannes H., Bachmann, Hagen S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423774/ https://www.ncbi.nlm.nih.gov/pubmed/30885150 http://dx.doi.org/10.1186/s12885-019-5439-1 |
Ejemplares similares
-
A 3′UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1
por: Akdeli, Neval, et al.
Publicado: (2014) -
Cryptotanshinone chemosensitivity potentiation by TW-37 in human oral cancer cell lines by targeting STAT3–Mcl-1 signaling
por: Yang, In-Hyoung, et al.
Publicado: (2020) -
Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells
por: Wang, Haixia, et al.
Publicado: (2015) -
The BCL2 -938C>A Promoter Polymorphism Is Associated with Risk for and Time to Aseptic Loosening of Total Hip Arthroplasty
por: Stelmach, Patrick, et al.
Publicado: (2016) -
SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
por: Al-Katib, Ayad M, et al.
Publicado: (2009)